Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VNDA
VNDA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNDA News
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
Apr 10 2026
NASDAQ.COM
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
Apr 09 2026
Yahoo Finance
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
Apr 09 2026
PRnewswire
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
Apr 09 2026
Newsfilter
VANDA PHARMACEUTICALS INC - PLAN AIMS TO REMOVE FDA'S 180-DAY NDA REVIEW OBLIGATION
Apr 09 2026
moomoo
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS in GLP-1 Therapy
Apr 08 2026
Newsfilter
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS to Prevent Vomiting
Apr 08 2026
PRnewswire
EMA's CHMP Reaffirms Decision to Deny Change in Marketing Authorization for Hetlioz (Tasimelteon)
Mar 27 2026
moomoo
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development
Mar 19 2026
PRnewswire
Vanda Pharmaceuticals Raises Concerns Over FDA's New Draft Guidance
Mar 19 2026
Newsfilter
Wall Street Analysts Adjust Ratings
Mar 05 2026
Benzinga
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
Mar 03 2026
seekingalpha
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
Mar 03 2026
stocktwits
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
Mar 03 2026
PRnewswire
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
Mar 03 2026
Newsfilter
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
Feb 26 2026
PRnewswire
Show More News
